Additionally, a biomarker panel comprising plasma GFAP and neurofilament light chain (NfL), along with other established AD risk factors like age, sex, and APOE genotype, yielded an AUC of 0.91 in differentiating cognitively unimpaired from AD dementia subjects; an AUC of 0.81 for differentiating cognitively unimpaired from MCI subjects; and an AUC of 0.87 in predicting Aβ positivity [107]. Here, GFAP is linked to Alzheimer disease.